Enfortumab vedotin (EV), a drug antibody complex directed against nectin-4 shown to be highly expressed in urothelial carcinoma (UC), was FDA approved in late 2023 as a combination therapy approach with Pembrolizumab for patients with locally advanced or metastatic BC [11]. The gene discussed is NECTIN4; the disease is urothelial carcinoma.